Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1001b in IDH1 Mutated WHO Grade II Glioma
NCT04458272Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of safusidenib in glioma, sponsored by Daiichi Sankyo Co., Ltd.. Started Jul 2020; status: active, not recruiting.
02
Drugs
safusidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04458272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458272.